NSE · DRREDDY.NS
Dr. Reddy's Laboratories Limited
₹1,345.00+₹9.60 (+0.72%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
Loading market information…
NSE · ZYDUSLIFE.NS · INR
Stock price, dividends, earnings
Quote as of Oct 29, 2026, 09:59 AM UTC. Cached market data; not a live quote.
One-year closing-price history · INR. Historical prices are not a forecast.
Zydus Lifesciences Limited’s quoted price sits in the upper half of its reported 52-week range, 3.87% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
THE INCOME SIDE
Zydus Lifesciences Limited’s forward annual dividend is ₹1.00 per share, paid annual. The forward yield is 0.08% at the quoted price. Future payments can change.
Historical amounts are adjusted for stock splits. Understand ex-dividend and payment dates →
BEHIND THE RESULTS
Zydus Lifesciences Limited’s next earnings report is currently expected on Nov 4, 2026, with estimated earnings per share of ₹8.48. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Zydus Lifesciences Limited’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Zydus Lifesciences Limited, an Indian enterprise founded in Ahmedabad in 1952, operates globally in the pharmaceutical and consumer goods sectors. Renamed from Cadila Healthcare Limited in February 2022, the company manages the entire lifecycle of pharmaceutical products, from research and development to manufacturing, marketing, and distribution. Its extensive reach covers India, the United States, Europe, Latin America, the Asia Pacific region, and Africa. The company's pharmaceutical division provides a broad spectrum of offerings, including finished dosage human formulations (such as generics, branded generics, and specialized treatments like biosimilars and vaccines), as well as active pharmaceutical ingredients (APIs). Zydus focuses on therapeutic areas like pain management, neurology, dermatology, and liver diseases, among others. Additionally, it is developing a pipeline of biological products aimed at conditions such as oncology, autoimmune disorders, nephrology, ophthalmology, inflammation, rheumatology, hepatology, and infectious diseases. In its consumer products segment, Zydus offers popular wellness brands including Complan, the EverYuth range of skincare products, Nycil, Glucon-D glucose powder, Nutralite, and the Nutralite Doodhshakti dairy product line. Beyond these core operations, the company is also involved in investment activities, animal health and veterinary services, pharmacy retail, and human resource supply and administration.
Latest available per-share figures in INR. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 02:19 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
Completed calendar years and any current-year payments shown separately. Current-year totals are incomplete until all payments are made.
See annual income at the current dividend rate.
Assumes the annual dividend stays unchanged. Payments follow the company’s schedule. Excludes taxes, fees and currency changes.
| Q4 2025 | May 20, 2025 | ₹11.64-11.55% vs estimate | ₹65.28B+1.35% vs estimate |
|---|
| Q3 2025 | Feb 5, 2025 | ₹9.50+3.49% vs estimate | ₹52.69B+0.9% vs estimate |
|---|
| Q2 2025 | Nov 12, 2024 | ₹9.06+3.19% vs estimate | ₹52.37B+0.57% vs estimate |
|---|
KEEP COMPARING
₹1,345.00+₹9.60 (+0.72%)
Dr. Reddy's Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 4.94% below the high.
₹1,358.00-₹7.60 (-0.56%)
Cipla Limited’s quoted price sits in the lower half of its reported 52-week range, 14.77% below the high.
₹2,469.30-₹20.70 (-0.83%)
Mankind Pharma Limited’s quoted price sits in the upper half of its reported 52-week range, 6.54% below the high.
₹1,989.90+₹17.20 (+0.87%)
Lupin Limited’s quoted price sits in the lower half of its reported 52-week range, 21.33% below the high.
₹5,079.00+₹9.00 (+0.18%)
Alkem Laboratories Limited’s quoted price sits in the lower half of its reported 52-week range, 14.4% below the high.
₹1,926.20-₹4.30 (-0.22%)
Ipca Laboratories Limited’s quoted price sits in the upper half of its reported 52-week range, 5.49% below the high.
₹1,922.90+₹9.50 (+0.5%)
Wockhardt Limited’s quoted price sits in the upper half of its reported 52-week range, 20.62% below the high.
₹1,397.40-₹2.00 (-0.14%)
Alivus Life Sciences Limited’s quoted price sits in the upper half of its reported 52-week range, 6.45% below the high.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
